Social Media Impact of the 66th ASH Annual Meeting & Exposition 2024

ASH stand-1The ASH Annual Meeting & Exposition 2024 took place from December 7th to 10th, 2024, in San Diego, USA.

This year’s event was primarily an in-person event with virtual broadcasts available.

With this social media analysis, we will be assessing the impact of the congress online.

 

Scope

 

   The scope of the analysis is focused on mentions coming worldwide.*

 

   There were a total of 10K mentions from HCPs recorded during the listening period from November 30th, 2024, to December 17th, 2024 (one week before and one week after the conference).

   All mentions came from X.

  A total of 1,2K unique authors were identified.

 *#ash24 OR #ash2024 OR #ASHTrainee OR #ASHkudos OR #ASHRunWalk OR #ASHaiku

 

 Methodology

 

Capture d’écran 2025-02-24 110828

 

 

 

Volume of conversations

The peak of conversations happened during the conference representing 72% of mentions recorded during the listening period.

Volume of mentions overtime ASH 2024: HCPs

Capture d’écran 2025-02-24 111056

 

 

 

Top hashtags

 

79c4310b-c1b9-4029-80d4-9b440d1c9368

The top hashtag was
#mmsm
(multiple myeloma social media) demonstrating that development around multiple myeloma benefited from the most exposure. .

The official hashtag #ash24 was unsurprisingly the most used one. Of note the use of the hashtag #imfash2024 (International Myeloma Foundation ASH 2024) tying to an uptick in exposure multiple myeloma enjoyed this year.

 

 

 

 

 

 

Share of Voice (SOV) of medical conditions most discussed (# of mentions): multiple myeloma, mantle cell lymphoma, and chronic lymphocytic leukemia dominated online discussions.

 

Capture d’écran 2025-02-24 112448

 

Focus on multiple myeloma: daratumumab opens up new possibilities for high-risk smouldering multiple myeloma patients.

 

The AQUILA study was by far the most discussed clinical trial pertaining to multiple myeloma.

The portion of the study presented at ASH were focused on smouldering multiple myeloma and evaluated whether daratumumab provided superior outcomes than the current standard of care.



Topics of discussions (type of treatment)

Capture d’écran 2025-02-24 113110Capture d’écran 2025-02-24 113938

Volume of mentions

Capture d’écran 2025-02-24 114033

 

Most mentioned clinical trials

Design sans titre (34)

 

👇 Interested in the full report? You can access it here 👇

Access the full SML ASH 2024 report

 

 

 

 

Find out more about Social Media Intelligence just here!